Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 334


Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.

Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stål O, Malmström P, Fernö M, Rydén L, Hegardt C, Borg Å, Ringnér M.

Mol Oncol. 2012 Oct;6(5):494-506. doi: 10.1016/j.molonc.2012.06.002. Epub 2012 Jun 20.


Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.

Tan D, Tang P, Huang J, Zhang J, Zhou W, Walker AM.

Chin Med J (Engl). 2014;127(6):1077-83.


Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).

Changchien YC, Tátrai P, Papp G, Sápi J, Fónyad L, Szendrői M, Pápai Z, Sápi Z.

J Transl Med. 2012 Oct 30;10:216. doi: 10.1186/1479-5876-10-216.


EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.

Guo S, Li X, Rohr J, Wang Y, Ma S, Chen P, Wang Z.

Diagn Pathol. 2016 Apr 26;11:41. doi: 10.1186/s13000-016-0491-5.


Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.

Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, Santi M, Thompson CB, Judkins AR.

Brain Pathol. 2013 Sep;23(5):558-64. doi: 10.1111/bpa.12042. Epub 2013 Mar 6.


The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.

Bae WK, Yoo KH, Lee JS, Kim Y, Chung IJ, Park MH, Yoon JH, Furth PA, Hennighausen L.

Mol Carcinog. 2015 Oct;54(10):1172-80. doi: 10.1002/mc.22188. Epub 2014 Jul 7.


Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.

Tsang DP, Wu WK, Kang W, Lee YY, Wu F, Yu Z, Xiong L, Chan AW, Tong JH, Yang W, Li MS, Lau SS, Li X, Lee SD, Yang Y, Lai PB, Yu DY, Xu G, Lo KW, Chan MT, Wang H, Lee TL, Yu J, Wong N, Yip KY, To KF, Cheng AS.

J Pathol. 2016 Apr;238(5):651-64. doi: 10.1002/path.4688.


H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.

Chen S, Chen J, Zhan Q, Zhu Y, Chen H, Deng X, Hou Z, Shen B, Chen Y, Peng C.

Oncotarget. 2014 Nov 15;5(21):10421-33.


Expression of polycomb targets predicts breast cancer prognosis.

Jene-Sanz A, Váraljai R, Vilkova AV, Khramtsova GF, Khramtsov AI, Olopade OI, Lopez-Bigas N, Benevolenskaya EV.

Mol Cell Biol. 2013 Oct;33(19):3951-61. doi: 10.1128/MCB.00426-13. Epub 2013 Aug 5.


Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.

Tan D, Tan S, Zhang J, Tang P, Huang J, Zhou W, Wu S.

Chin J Physiol. 2013 Oct 31;56(5):282-90. doi: 10.4077/CJP.2013.BAB139. Epub 2013 Aug 31. Erratum in: Chin J Physiol. 2013 Dec 31;56(6):362.


EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.

Chinaranagari S, Sharma P, Chaudhary J.

Oncotarget. 2014 Aug 30;5(16):7172-82.


EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.

Fu Y, Chen J, Pang B, Li C, Zhao J, Shen K.

Cell Biochem Biophys. 2015 Jan;71(1):105-12. doi: 10.1007/s12013-014-0168-1.


The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.

Ngollo M, Lebert A, Dagdemir A, Judes G, Karsli-Ceppioglu S, Daures M, Kemeny JL, Penault-Llorca F, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D.

BMC Cancer. 2014 Dec 23;14:994. doi: 10.1186/1471-2407-14-994.


Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.

Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter JN, Licht JD, Chen YH.

Leuk Lymphoma. 2015;56(10):2895-901. doi: 10.3109/10428194.2015.1006220. Epub 2015 Mar 8.


EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.

Granit RZ, Gabai Y, Hadar T, Karamansha Y, Liberman L, Waldhorn I, Gat-Viks I, Regev A, Maly B, Darash-Yahana M, Peretz T, Ben-Porath I.

Oncogene. 2013 Aug 15;32(33):3886-95.


EZH2 methyltransferase and H3K27 methylation in breast cancer.

Yoo KH, Hennighausen L.

Int J Biol Sci. 2012;8(1):59-65. Epub 2011 Nov 18. Review.


A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.

Ott HM, Graves AP, Pappalardi MB, Huddleston M, Halsey WS, Hughes AM, Groy A, Dul E, Jiang Y, Bai Y, Annan R, Verma SK, Knight SD, Kruger RG, Dhanak D, Schwartz B, Tummino PJ, Creasy CL, McCabe MT.

Mol Cancer Ther. 2014 Dec;13(12):3062-73. doi: 10.1158/1535-7163.MCT-13-0876. Epub 2014 Sep 24.


Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.

Gannon OM, Merida de Long L, Endo-Munoz L, Hazar-Rethinam M, Saunders NA.

Clin Cancer Res. 2013 Jan 15;19(2):428-41. doi: 10.1158/1078-0432.CCR-12-2505. Epub 2012 Nov 27.


EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL.

Nature. 2012 Dec 6;492(7427):108-12. doi: 10.1038/nature11606. Epub 2012 Oct 10.


Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.

Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q.

Mol Cancer Ther. 2009 Dec;8(12):3191-202. doi: 10.1158/1535-7163.MCT-09-0479.

Supplemental Content

Support Center